SNBL

OverviewSuggest Edit

Shin Nippon Biomedical Laboratories (SNBL Japan, 株式会社 新日本科学) is a contract research organization specializing in preclinical and clinical studies. It offers GLP (good laboratory practice), toxicity, pathology, pharmacokinetics, translational, and other research services. The company serves the pharmaceutical industry.

TypePublic
Founded1957
HQChuo City, JP
Websitesnbljapan.com
Employee Ratings2.6

Latest Updates

Employees (est.) (Jun 2022)994
Revenue (FY, 2022)¥17.7 B(+18%)
Share Price (Aug 2022)¥1.9 K(-1%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at SNBL

Ryoichi Nagata

Ryoichi Nagata

Chairman, President & CEO
Hideshi Tsusaki

Hideshi Tsusaki

President, Preclinical Services
Satoshi Matsumoto

Satoshi Matsumoto

Exective Director
Show more

SNBL Office Locations

SNBL has offices in Chuo City, Kagoshima, Kobe, Minato City and in 4 other locations
Chuo City, JP (HQ)
St Luke's Tower 28F, 8-1 Akashi-cho, Chuo-ku, Tokyo,104-0044, Japan
Kobe, JP
1-chōme-6-5 Minatojima Minamimachi, Chūō-ku
Minato City, JP
Akasaka
Osaka, JP
1 Chome-1 Fushimimachi, Chuo Ward
Tsukuba, JP
2-chōme-1-6 Sengen
Everett, WA, US
6605 Merrill Creek Pkwy
Show all (8)

SNBL Financials and Metrics

SNBL Revenue

Embed Graph
View revenue for all periods
SNBL's revenue was reported to be ¥17.75 b in FY, 2022
JPY

Revenue (FY, 2022)

17.7b

Gross profit (FY, 2022)

10.7b

Gross profit margin (FY, 2022), %

60.3%

Net income (FY, 2022)

7.2b

EBITDA (FY, 2022)

7.1b

EBIT (FY, 2022)

5.7b

Market capitalization (2-Aug-2022)

82.1b

Closing stock price (2-Aug-2022)

1.9k

Cash (31-Mar-2022)

6.6b

EV

84.6b
SNBL's current market capitalization is ¥82.1 b.
Annual
JPYFY, 2018FY, 2019FY, 2020FY, 2021FY, 2022

Revenue

16.6b15.7b14.6b15.1b17.7b

Cost of goods sold

(10.2b)(8.3b)(5.9b)(6.5b)(7.0b)

Gross profit

6.4b7.3b8.7b8.6b10.7b

Gross profit Margin, %

39%47%60%57%60%
Quarterly
JPYQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022Q2, 2022Q3, 2022

Revenue

3.7b5.2b3.4b2.7b3.7b3.7b3.2b3.8b3.4b3.0b4.9b5.0b

Cost of goods sold

(2.1b)(3.0b)(1.5b)(966.1m)(1.4b)(1.6b)(1.3b)(1.7b)(1.5b)(1.2b)(1.9b)(2.0b)

Gross profit

1.6b2.1b1.9b1.8b2.3b2.0b1.9b2.1b1.9b1.8b3.0b3.0b

Gross profit Margin, %

43%42%55%65%63%55%59%56%56%61%62%60%
Annual
JPYFY, 2018FY, 2019FY, 2020FY, 2021FY, 2022

Cash

5.3b5.1b5.2b7.2b6.6b

Accounts Receivable

2.5b1.9b2.5b3.0b3.5b

Inventories

6.4b3.6b4.0b4.1b4.4b
Quarterly
JPYQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022Q2, 2022Q3, 2022

Cash

4.8b5.7b4.7b4.1b4.6b4.0b6.2b5.4b6.4b5.4b5.3b5.6b

Accounts Receivable

1.5b1.8b1.8b1.6b1.6b2.1b2.0b2.4b2.5b2.0b2.4b3.1b

Inventories

6.5b3.8b3.7b4.2b4.2b4.2b4.2b4.1b4.2b4.3b4.3b4.2b
Annual
JPYFY, 2018FY, 2019FY, 2020FY, 2021FY, 2022

Net Income

(1.5b)1.7b3.1b4.2b8.2b

Depreciation and Amortization

1.5b1.4b1.2b1.2b1.2b

Inventories

398.3m(424.5m)(445.3m)(71.7m)(371.1m)

Accounts Payable

(2.3m)119.2m82.7m(24.2m)(36.7m)
Quarterly
JPYQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022Q2, 2022Q3, 2022

Net Income

629.1m1.3b1.3b3.9b

Depreciation and Amortization

788.7m563.6m574.8m560.9m

Inventories

(547.8m)(646.1m)(37.2m)(373.7m)

Accounts Payable

195.2m39.5m(25.9m)(57.6m)
JPYFY, 2018

Debt/Equity

0.7 x

Debt/Assets

0.3 x

Financial Leverage

2.2 x
Show all financial metrics

SNBL Operating Metrics

Nov, 2020

Awards

2

Patents (US)

26

Trademarks (US)

5

Types of Services

4

SNBL Acquisitions / Subsidiaries

Company NameDateDeal Size
Gemseki Inc

SNBL Revenue Breakdown

Embed Graph

SNBL revenue breakdown by business segment: 5.5% from OTHER NONDISCLOSED, 96.1% from OTHER SCHOOLS and -1.5% from Other

SNBL revenue breakdown by geographic segment: 100.0% from JAPAN

SNBL Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

SNBL Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

SNBL Online and Social Media Presence

Embed Graph

SNBL News and Updates

Is SNBL more sustainable than BNPL? (Joris Lochy)

In my blog "Buy Now Pay Later - A credit in disguise? (https://www.finextra.com/blogposting/206...

SNBL to participate in development of a prophylactic DNA vaccine for COVID-19

SNBL has announced their intention to participate in the development of a prophylactic DNA vaccine for SARS-CoV-2, the disease which causes COVID-19.

Japan's State of Emergency and SNBL

On April 7, 2020, Japanese Prime Minister Shinzo Abe declared a state of emergency in 7 areas of Japan due to COVID-19, including large cities such as Tokyo and Osaka. This does not apply to the areas in which SNBL's two major laboratories are located.

SNBL Client CytoDyn Files IND for Respiratory Complications Therapy due to COVID-19

A client of Shin Nippon Biomedical Laboratories, Ltd. (hereafter, SNBL), CytoDyn Inc. (Vancouver, Washington, USA, hereafter CytoDyn) has filed an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) in order to conduct a Phase 2 clinical trial using leronlimab (…

SNBL to be represented by Medgaea Life Sciences, Ltd. in Taiwan

SNBL and Medgaea Life Sciences, Ltd. (MDG) have signed an agreement for Medgaea Life Sciences to represent SNBL in Taiwan.

SNBL Blogs

FY2022/3 Full Year Financial Results and Supplementary Information

SNBL announced the consolidated financial results for the fiscal year ended March 31, 2022 and supplementary information today. For details, please check the links below: Consolidated Financial Results for the Fiscal Year Ended March 31, 2022 (Under Japanese GAAP…

FY2022 Third Quarter Financial Results and Business Updates

SNBL announced the financial results for the third quarter ended December 31, 2021 and revisions to the full-year earnings and year-end dividend forecasts. For more details, please check the links below: Consolidated Financial Results for the Nine Months of the Fisc…

Consolidated Financial Results for the Six Months of the Fiscal Year Ending March 31, 2022

Consolidated Financial Results for the Six Months of the Fiscal Year Ending March 31, 2022 Financial Results 1H FY202203.pdf Adobe Acro…

Revisions of the Earnings Forecasts for the Six Months and Full-Year of the FY Ending March 31, 2022

SNBL revised its earnings forecasts for the six months and full-year of the fiscal year ending March 31, 2022. Revisions of the Earnings Forecasts 1H & Full-Year FY2022/3 …

Notice Regarding Establishment of SDGs Committee

SNBL has established a Sustainable Developmental Goals (SDGs) committee. Please see the link below for more details. Notice Regarding Establishment of SDGs Committee …

SNBL Frequently Asked Questions

  • When was SNBL founded?

    SNBL was founded in 1957.

  • Who are SNBL key executives?

    SNBL's key executives are Ryoichi Nagata, Hideshi Tsusaki and Satoshi Matsumoto.

  • How many employees does SNBL have?

    SNBL has 994 employees.

  • What is SNBL revenue?

    Latest SNBL annual revenue is ¥17.7 b.

  • What is SNBL revenue per employee?

    Latest SNBL revenue per employee is ¥17.9 m.

  • Who are SNBL competitors?

    Competitors of SNBL include Envigo, WuXi AppTec and Charles River Laboratories.

  • Where is SNBL headquarters?

    SNBL headquarters is located at St Luke's Tower 28F, 8-1 Akashi-cho, Chuo-ku, Tokyo,104-0044, Japan, Chuo City.

  • Where are SNBL offices?

    SNBL has offices in Chuo City, Kagoshima, Kobe, Minato City and in 4 other locations.

  • How many offices does SNBL have?

    SNBL has 8 offices.